Oral Calcitriol Use, Vertebral Fractures, and Vitamin K in Hemodialysis Patients: A Cross-Sectional Study
Open Access
- 1 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 36 (12) , 2361-2370
Abstract
Fractures and vascular calcifications (VCs) are common in patients with chronic kidney disease (CKD). They are related to abnormalities in vitamin D metabolism, calcium, phosphorus, parathyroid hormone, and fibroblast growth factor 23 (FGF23)/Klotho that occur with CKD. Impaired vitamin D metabolism and abnormal levels of calcium, phosphate, parathyroid hormone (PTH), and FGF23/Klotho drive bone and vascular changes in CKD. It is unclear if oral calcitriol safely mitigates fracture risk without increasing the burden of calcifications. Therefore, we investigated whether treatment with calcitriol affected the prevalence of fractures and VC progression in hemodialysis (HD) patients. This report is a secondary analysis of the Vitamin K Italian (VIKI) study, a cross-sectional study involving 387 HD patients. We assessed vitamin 25(OH)D, alkaline phosphatase, PTH, calcium, phosphate, osteocalcin or bone Gla protein, matrix Gla protein, and vitamin K levels. Vertebral fractures (VFs) and VCs were determined by spine radiograph. A reduction of >20% of vertebral body height was considered a VF. VCs were quantified by the length of calcific lesions along the arteries. The patients treated with oral calcitriol were 177 of 387 patients (45.7%). The prevalence of VF was lower in patients receiving oral calcitriol than in those untreated (48.6% versus 61.0%, p = 0.015), whereas the presence of aortic and iliac calcifications was similar (aortic: 81.9% versus 79.5%, respectively, p = 0.552; iliac: 52.0% and 59.5%, respectively, p = 0.167). In multivariable logistic regression analysis, oral calcitriol was associated with a 40.2% reduced odds of fracture (OR 0.598; 95% confidence interval [CI], 0.363–0.985; p = 0.043). In conclusion, we found a significant association between oral calcitriol and lower VF in HD patients without an increase in the burden of VC. Further prospective and interventional studies are needed to confirm these findings. © 2021 American Society for Bone and Mineral Research (ASBMR).Keywords
This publication has 60 references indexed in Scilit:
- Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis studyJournal of Bone and Mineral Research, 2012
- The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative reviewOsteoporosis International, 2009
- Vitamin D Affects Survival Independently of Vascular Calcification in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and fallsJournal of Bone and Mineral Metabolism, 2008
- Vascular calcifications, vertebral fractures and mortality in haemodialysis patientsNephrology Dialysis Transplantation, 2008
- Vitamin D Receptor Activators Can Protect against Vascular CalcificationJournal of the American Society of Nephrology, 2008
- The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic ratsKidney International, 2008
- Paricalcitol [19-Nor-1,25-(OH)2D2] in the Treatment of Experimental Renal Bone DiseaseJournal of Bone and Mineral Research, 2006
- Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failureNephrology Dialysis Transplantation, 2004
- Evidence for the formation of a complex between osteopontin and osteocalcinJournal of Bone and Mineral Research, 1992